Loading...
Please wait, while we are loading the content...
Similar Documents
VEGF is a target molecule for peritoneal metastasis and malignant ascites in gastric cancer: prognostic significance of VEGF in ascites and efficacy of anti-VEGF monoclonal antibody.
| Content Provider | Europe PMC |
|---|---|
| Author | Fushida, Sachio Oyama, Katsunobu Kinoshita, Jun Yagi, Yasumichi Okamoto, Kouichi Tajima, Hidehiro Ninomiya, Itasu Fujimura, Takashi Ohta, Tetsuo |
| Copyright Year | 2013 |
| Abstract | BackgroundIn gastric cancer, poor prognosis is associated with peritoneal dissemination, which often accompanies malignant ascites. We searched for a target molecule in peritoneal metastasis and investigated its clinical utility as a biomarker.MethodsBiopsy specimens from both primary lesions and peritoneal metastasis, and if possible, malignant ascites, were obtained from 40 patients with gastric cancer. Vascular endothelial growth factor (VEGF) expression was analyzed by immunohistochemical staining and enzyme-linked immunosorbent assay.ResultsVEGF expression was seen in 70% of peritoneal samples. Of the 40 patients, 35 had malignant ascites. These 35 patients were divided into two groups: 15 with ascites found beyond the pelvic cavity (large group) and 20 whose ascites were within the pelvic cavity (small group). The two groups did not significantly differ by serum VEGF levels, but ascites VEGF levels in the large group were significantly higher than in the small group (P < 0.0001). Serum VEGF and ascites VEGF levels were highly correlated in the large group (r = 0.686). A high ascites VEGF level was found to be a risk factor for survival (P = 0.045). We include a report of a patient with chemoresistant refractory gastric cancer and symptomatic ascites who obtained 8 months of palliation from systemic bevacizumab.ConclusionAnti-VEGF therapies are promising, and the ascites VEGF level is an important marker in managing patients with gastric cancer and peritoneal metastasis. |
| Journal | Oncotargets and Therapy |
| Volume Number | 6 |
| PubMed Central reference number | PMC3804591 |
| PubMed reference number | 24204159 |
| e-ISSN | 11786930 |
| DOI | 10.2147/ott.s51916 |
| Language | English |
| Publisher | Dove Medical Press |
| Publisher Date | 2013-10-16 |
| Access Restriction | Open |
| Rights License | The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. © 2013 Fushida et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License |
| Subject Keyword | vascular endothelial growth factor malignant ascites peritoneal metastasis gastric cancer bevacizumab |
| Content Type | Text |
| Resource Type | Article |
| Subject | Pharmacology (medical) Oncology |
